Plozasiran

DRUG4 trials

Sponsors

Arrowhead Pharmaceuticals, Visirna Therapeutics HK Limited

Conditions

Familial ChylomicronemiaFamilial Chylomicronemia SyndromeHigh Risk Severe Hypertriglyceridemia (SHTG)Severe Hypertriglyceridemia

Phase 3

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

CompletedNCT05089084

Arrowhead PharmaceuticalsFamilial Chylomicronemia

Start: 2021-12-14End: 2026-04-21Updated: 2026-06-05

A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome

CompletedNCT05902598

Visirna Therapeutics HK LimitedFamilial Chylomicronemia Syndrome

Start: 2023-07-10End: 2026-01-09Updated: 2026-02-27

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

RecruitingNCT06880770

Arrowhead PharmaceuticalsSevere Hypertriglyceridemia

Start: 2025-04-24End: 2029-06-01Target: 288Updated: 2026-09-02

Unknown Phase

Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS

Arrowhead PharmaceuticalsFamilial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG)

Updated: 2026-03-03

Related Papers

Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia—Results of a Post Hoc Analysis of the Phase 3 <scp>PALISADE</scp> Study

Alimentary Pharmacology & Therapeutics2026-04-011 citations

Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk

New England Journal of Medicine2024-09-02104 citations